Diamyd Medical AB (publ) (FRA:DMN)

Germany flag Germany · Delayed Price · Currency is EUR
0.860
-0.005 (-0.58%)
Last updated: Dec 5, 2025, 8:03 AM CET
-28.33%
Market Cap 123.82M
Revenue (ttm) 11.73K
Net Income (ttm) -15.32M
Shares Out n/a
EPS (ttm) -0.14
PE Ratio n/a
Forward PE 21.23
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 21
Open 0.860
Previous Close 0.865
Day's Range 0.860 - 0.860
52-Week Range 0.649 - 1.624
Beta n/a
RSI 48.57
Earnings Date Jan 28, 2026

About Diamyd Medical AB

Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to devel... [Read more]

Industry Pharmaceutical Preparations
Founded 1984
Employees 39
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol DMN
Full Company Profile

Financial Performance

In 2025, Diamyd Medical AB's revenue was 130,000, a change of 0.00% compared to the previous year's 130,000. Losses were -169.78 million, 11.8% more than in 2024.

Financial numbers in SEK Financial Statements

News

There is no news available yet.